Health Research Alliance
2016_Hum_Molec_Genet.pdf (1.02 MB)


Download (1.02 MB)
journal contribution
posted on 2019-03-06, 14:04 authored by Brian Stansfield

Persons with neurofibromatosis type 1 (NF1) have a predisposition for premature and severe arterial stenosis. Mutations in the NF1 gene result in decreased expression of neurofibromin, a negative regulator of p21Ras, and increases Ras signaling. Heterozygous Nf1 (Nf1+/−) mice develop a marked arterial stenosis characterized by proliferating smooth muscle cells (SMCs) and a predominance of infiltrating macrophages, which closely resembles arterial lesions from NF1 patients. Interestingly,

lineage-restricted inactivation of a single Nf1 allele in monocytes/macrophages is sufficient to recapitulate the phenotype observed in Nf1+/− mice and to mobilize proinflammatory CCR2+ monocytes into the peripheral blood. Therefore, we hypothesized that CCR2 receptor activation by its primary ligand monocyte chemotactic protein-1 (MCP-1) is critical for monocyte infiltration into the arterial wall and neointima formation in Nf1+/− mice. MCP-1 induces a dose-responsive increase in Nf1+/− macrophage migration and proliferation that corresponds with activation of multiple Ras kinases. In addition, Nf1+/− SMCs, which express CCR2, demonstrate an enhanced proliferative response to MCP-1 when compared with WT SMCs. To interrogate the role of CCR2 activation on Nf1+/− neointima formation, we induced neointima formation by carotid artery ligation in Nf1+/− and WT mice with genetic deletion of either MCP1 or CCR2. Loss of MCP-1 or CCR2 expression effectively

inhibited Nf1+/− neointima formation and reduced macrophage content in the arterial wall. Finally, administration of a CCR2 antagonist significantly reduced Nf1+/− neointima formation. These studies identify MCP-1 as a potent chemokine for Nf1+/− monocytes/macrophages and CCR2 as a viable therapeutic target for NF1 arterial stenosis.


Grant ID